Monday, April 1, 2019

Cipla signs $22 mn pact with Pulmatrix Inc for new asthma drug

Cipla signs $22 mn pact with Pulmatrix Inc for new asthma drug Pulmazole is an inhaled anti-fungal formulation of itraconazole aimed at treating allergic bronchopulmonary aspergillosis (ABPA) in asthma patients.

from Moneycontrol Business News https://ift.tt/2TNWWab

No comments:

Post a Comment

Paras Defence shares soar 10% as Q2 net profit jumps 50% to Rs 14 crore

Paras Defence and Space Technologies shares surged following strong September quarter results, with net profit jumping 50% and revenue climb...